Want to see IN:ANURAS full AI Analyst Report?
Anupam Rasayan India Ltd. (ANURAS) AI Stock Analysis
Anupam Rasayan India Ltd.
(NSE:ANURAS)
Financial performance at 67 drives the score with growth prospects tempered by cash flow inconsistency; technical signals are mixed while high valuation metrics reduce the overall result.
Anupam Rasayan India Ltd. (ANURAS) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 130.19B
- Dividend Yield
- 0.13%
- Average Volume (3M)
- 11.96K
- Price to Earnings (P/E)
- 74.3
- Beta (1Y)
- 0.73
- Revenue Growth
- 51.77%
- EPS Growth
- 36.90%
- Country
- India
- Employees
- 2,606
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals - Specialty
Anupam Rasayan India Ltd. Business Overview & Revenue Model
Company Description
Anupam Rasayan India Ltd., established in Surat, India, in 1984, specializes in the custom synthesis and production of specialty chemicals. The company manufactures a diverse range of life science-oriented chemicals, including intermediates and activ...
Anupam Rasayan India Ltd. Financial Statement Overview
Summary
Revenue growth potential and solid balance sheet expansion are offset by cash flow volatility and recent revenue declines.
Income Statement
70PositiveBalance Sheet
75PositiveCash Flow
55Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.35B | 23.65B | 14.42B | 14.80B | 16.02B | 10.74B |
| Gross Profit | 9.27B | 8.16B | 8.22B | 8.51B | 8.85B | 7.02B |
| EBITDA | 5.76B | 5.43B | 4.07B | 3.87B | 4.32B | 3.05B |
| Net Income | 1.75B | 1.70B | 933.49M | 1.29B | 1.81B | 1.52B |
Balance Sheet | ||||||
| Total Assets | 0 | 80.13B | 52.69B | 46.02B | 37.78B | 28.91B |
| Cash, Cash Equivalents and Short-Term Investments | 4.11B | 4.11B | 1.35B | 3.48B | 6.67B | 618.77M |
| Total Debt | 0 | 18.67B | 13.73B | 10.70B | 8.22B | 8.36B |
| Total Liabilities | -46.30B | 33.83B | 21.87B | 16.71B | 12.70B | 11.64B |
| Stockholders Equity | 46.30B | 33.34B | 28.50B | 27.61B | 23.73B | 17.27B |
Cash Flow | ||||||
| Free Cash Flow | 3.28B | -3.57B | -4.40B | -6.57B | 713.03M | -3.18B |
| Operating Cash Flow | 5.35B | 1.99B | -301.25M | 590.32M | 2.92B | -1.71B |
| Investing Cash Flow | -2.53B | -8.21B | -3.30B | -3.92B | -5.23B | -4.12B |
| Financing Cash Flow | 182.51M | 7.57B | 2.23B | 3.95B | 3.71B | 3.84B |
Anupam Rasayan India Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ANURAS, the sentiment is Negative. The current price of 1141.80 is below the 20-day moving average (MA) of 1143.60, below the 50-day MA of 1188.57, and below the 200-day MA of 1256.13, indicating a bearish trend. The MACD of -11.77 indicates Negative momentum. The RSI at 47.27 is Neutral, neither overbought nor oversold. The STOCH value of 75.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ANURAS.
Anupam Rasayan India Ltd. Peers Comparison
Overall Rating
IN:ATUL68Neutral
IN:ALKYLAMINE60Neutral- IN:ANURAS59Neutral
IN:AETHER55Neutral
IN:AARTIIND47Neutral
IN:JUBLINGREA46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:ATUL | 68Neutral | INR 147.89B | 19.18 | ― | 0.60% | 18.15% | 42.38% |
| IN:ALKYLAMINE | 60Neutral | INR 81.33B | 36.11 | ― | 0.63% | 5.11% | 20.64% |
| IN:ANURAS | 59Neutral | INR 129.99B | 74.35 | ― | 0.13% | 51.77% | 36.90% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:AETHER | 55Neutral | INR 215.08B | 90.95 | ― | ― | 30.76% | 28.12% |
| IN:AARTIIND | 47Neutral | INR 157.96B | 29.74 | ― | 0.23% | 39.85% | 103.71% |
| IN:JUBLINGREA | 46Neutral | INR 89.05B | 25.14 | ― | 0.89% | 15.41% | 21.76% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ANURAS | Anupam Rasayan India Ltd. | 1141.80 | 61.23 | 5.67% | |
| IN:AARTIIND | AARTI Industries Ltd | 435.45 | 47.72 | 12.31% | |
| IN:AETHER | Aether Industries Ltd. | 1620.45 | 859.30 | 112.89% | |
| IN:ALKYLAMINE | Alkyl Amines Chemicals Limited | 1590.10 | -289.30 | -15.39% | |
| IN:ATUL | Atul Limited | 5023.05 | -852.49 | -14.51% | |
| IN:JUBLINGREA | Jubilant Ingrevia Ltd. | 559.05 | -127.98 | -18.63% |
Anupam Rasayan India Ltd. Corporate Events
Anupam Rasayan Secures Majority Control in Bliss GVS Pharma
Anupam Rasayan India Ltd. has completed the acquisition of a controlling stake in Bliss GVS Pharma Ltd., culminating a series of transactions under a previously announced share purchase agreement and open offer. Following on-market purchases and tend...
Anupam Rasayan Executes Security Documents Backing MVCPL Debentures
Anupam Rasayan India Ltd. has executed a debenture trust deed involving Mates Visa Consultancy Pvt. Ltd. and Catalyst Trusteeship Ltd., as part of a security package linked to debentures issued by MVCPL. The move formalizes arrangements under a previ...
Anupam Rasayan Pledges MVCPL Stake and Issues Corporate Guarantee for Debenture Structure
Anupam Rasayan India Ltd. has executed a debenture trust deed involving Mates Visa Consultancy Pvt. Ltd., Catalyst Trusteeship Ltd., and the debenture holders, formalising security arrangements around MVCPL’s debentures. As part of this structu...
Anupam Rasayan Raises INR 145 Crore via Secured Debenture Issue
Anupam Rasayan India Ltd. has allotted 14,500 senior secured, rated, unlisted, redeemable non-convertible debentures with a face value of INR 1,00,000 each, raising INR 145 crore from Aditya Birla Capital Ltd. The issuance, executed through a debentu...
Anupam Rasayan Board Clears INR 160 Crore NCD Issue for Debt Refinancing
Anupam Rasayan India Ltd.’s board has approved the private placement of up to 16,000 secured, rated, unlisted, redeemable non-convertible debentures, with a total size not exceeding INR 160 crore. The debentures will be issued in dematerialised...
Anupam Rasayan to Raise ₹160 Crore via Secured Non-Convertible Debentures
Anupam Rasayan India Ltd.’s board has approved the issuance of up to 16,000 secured, rated, unlisted and redeemable non-convertible debentures, each with a nominal value of ₹100,000, for a total amount not exceeding ₹160 crore on a...
Anupam Rasayan Files Q1 FY27 Results, Appoints New COO
Anupam Rasayan India Ltd. reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following a board meeting held on August 14. The results have undergone a limited review by the statutory auditor, who...
Anupam Rasayan Elevates Ravi Desai to Chief Operating Officer
Anupam Rasayan India Ltd. has appointed Ravi Desai as Chief Operating Officer, effective August 14, 2026, following approval by the board based on the Nomination and Remuneration Committee’s recommendation. Desai, who has been with the company...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 25, 2026